Systemic Therapy Principles for Metastatic Renal Cell Carcinoma
For first-line treatment of metastatic clear cell RCC, patients with intermediate- or poor-risk disease (IMDC 1-2 or 3+ points) should receive combination therapy with either dual immune checkpoint inhibitors (ipilimumab plus nivolumab) or an ICI combined with a VEGFR TKI 1, 2.
Risk Stratification is Mandatory
Before initiating any systemic therapy, stratify patients using the International Metastatic RCC Database Consortium (IMDC) criteria into three groups 1:
- Favorable risk: 0 risk factors
- Intermediate risk: 1-2 risk factors
- Poor risk: 3+ risk factors
This stratification directly determines treatment selection and is non-negotiable.
First-Line Treatment Algorithm
For Intermediate and Poor-Risk Disease (IMDC 1-2 or 3+)
Combination therapy is mandatory 1. Five approved regimens exist with strong evidence:
- Nivolumab plus ipilimumab (dual ICI)
- Nivolumab plus cabozantinib - achieved median PFS of 16.6 months versus 8.3 months with sunitinib (HR 0.51), with 12-month OS probability of 85.7% versus 75.6% 1
- Pembrolizumab plus axitinib - 24-month PFS of 34.3% versus 22.7% with sunitinib 1
- Avelumab plus axitinib
- Pembrolizumab plus lenvatinib
Selection between these regimens should be based on 1:
- Quality of life considerations
- Side effect profiles (75.3% grade 3+ adverse events with nivolumab/cabozantinib versus 70.6% with sunitinib alone)
- Comorbid conditions that may preclude ICIs or TKIs
- Out-of-pocket treatment costs
For Favorable-Risk Disease (IMDC 0)
Monotherapy with either a VEGFR TKI or an ICI is acceptable 1. Options include cabozantinib, pazopanib, sunitinib, axitinib, or pembrolizumab as single agents 1.
Active surveillance may be considered for highly selected patients with slow-growing, asymptomatic, low-volume disease 2.
Special Populations
For sarcomatoid features: ICI combination regimens are mandatory given consistently superior outcomes. In CheckMate 9ER, patients with sarcomatoid differentiation receiving nivolumab plus cabozantinib achieved median PFS of 10.9 versus 4.2 months (HR 0.39) and median OS not reached versus 19.7 months (HR 0.36) compared to sunitinib 1.
High-dose IL-2 may be considered but carries significant toxicity and has been largely replaced by modern immunotherapy regimens. It should only be administered in experienced high-volume centers, preferably within clinical trials 1.
Second-Line and Beyond Treatment Principles
After Progression on ICI Plus VEGFR TKI Combination
Switch to an alternate VEGFR TKI as monotherapy 1. This is strongly recommended based on high-quality evidence.
After Progression on VEGFR TKI Monotherapy
Two options with the strongest overall survival data 1:
- Cabozantinib - achieved OS of 20.4 months versus 17.1 months with everolimus (METEOR trial)
- Nivolumab - achieved OS of 25.8 months versus 19.7 months with everolimus (CheckMate 025)
Selection between cabozantinib and nivolumab depends on 1:
- Pace of disease progression (faster progression favors cabozantinib)
- Presence of disease-related symptoms (symptomatic disease favors cabozantinib)
- Patient comorbidities
- Financial toxicity and travel concerns
Alternative options with PFS benefit include axitinib or lenvatinib plus everolimus 1.
Limited Disease Progression on Immunotherapy
For oligoprogression (single site): Offer local therapy (radiation, thermal ablation, or excision) and continue the same immunotherapy 1. This allows patients to remain on effective systemic therapy while controlling isolated progression sites.
Metastasis-Directed Therapy
For low-volume metastatic disease: Definitive metastasis-directed therapies including surgical resection (metastasectomy), ablative measures, or radiotherapy should be offered 1.
Site-Specific Considerations
Bone Metastases
Offer bone resorption inhibitors (bisphosphonate or RANKL inhibitor) when clinical concern for fracture or skeletal-related events exists 1. While no specific systemic treatment recommendation can be made for bone metastases, expert consensus suggests cabozantinib-containing regimens may be preferred 1.
Critical Pitfalls to Avoid
- Do not skip IMDC risk stratification - this is the foundation of treatment selection
- Do not use monotherapy in intermediate/poor-risk patients unless specific contraindications exist
- Do not continue the same regimen after progression - switch therapeutic classes
- Do not perform cytoreductive nephrectomy routinely - systemic therapy should be prioritized in most cases, with surgery reserved for well-selected patients with low IMDC risk (0-1 points), low metastatic burden, and excellent performance status 2